GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Abeona Therapeutics
Abeona Therapeutics is a biotechnology company specializing in gene and cell therapy. Its stock price is highly volatile, driven by news of clinical trials of its drugs for the treatment of rare genetic diseases.
Share prices of companies in the market segment - Specialized pharma
Abeona Therapeutics (ABEO) is a biopharmaceutical company specializing in the development of gene and cell therapies for the treatment of rare and life-threatening diseases, particularly epidermolysis bullosa. We classify the company as a "Specialty Pharmaceutical." The chart below shows the dynamics of the orphan drug sector.
Broad Market Index - GURU.Markets
Abeona Therapeutics is a biopharmaceutical company developing gene and cell therapies for rare genetic diseases. As a component of the GURU.Markets index, it represents the orphan disease sector. The chart below represents the entire market. See how Abeona shares compare to the overall trend.
Change in the price of a company, segment, and market as a whole per day
ABEO - Daily change in the company's share price Abeona Therapeutics
The volatility of Abeona Therapeutics, a gene and cell therapy company, reflects the risks and hopes of the biotech sector. Change_co measures sensitivity to clinical trial results. This parameter is important for formulas on System.GURU.Markets that analyze high-risk biotech companies.
Daily change in the price of a set of shares in a market segment - Specialized pharma
Abeona Therapeutics Inc. is a biotech company. This chart highlights the extreme volatility of the sector. Comparison with ABEO, which focuses on cell and gene therapy, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Abeona is a biopharmaceutical company developing gene and cell therapies. This is a cutting-edge and highly speculative area of biotech. The chart below illustrates the high volatility typical of this sector, reflecting the risks and potential associated with Abeona's technologies.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Abeona Therapeutics
For Abeona Therapeutics, the year-over-year trend is a story of developing gene and cell therapies for rare skin diseases. Its 12-month market capitalization is crucially dependent on FDA decisions. Obtaining approval for its drugs is a fundamental event that could save patients' lives and transform the company into a successful commercial company.
Annual dynamics of market capitalization of the market segment - Specialized pharma
Abeona Therapeutics Inc. is a biotechnology company focused on developing gene and cell therapies for rare diseases. Its stock price is entirely dependent on clinical trial results and regulatory decisions. The chart reflects high risks and breakthrough potential.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Abeona Therapeutics is a biopharmaceutical company whose stock performance is driven by the commercialization of its products and progress in research. The company's business is not dependent on economic cycles. This chart reflects biotech events, not macroeconomic data.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Abeona Therapeutics
The value of Abeona, a gene and cell therapy company, is speculative. Monthly fluctuations on the chart reflect not revenue, but rather news about the progress of clinical trials and regulatory approvals for its drugs for rare genetic diseases.
Monthly dynamics of market capitalization of the market segment - Specialized pharma
Developing gene and cell therapies for rare diseases is the pinnacle of biotech innovation, fraught with enormous risks. The dynamics of this sector, as seen in the chart, reflect the hopes and fears of investors. In this challenging environment, companies like Abeona Therapeutics are striving to create breakthrough treatments.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Abeona Therapeutics, which specializes in gene and cell therapy, is a biotech venture bet. The company's share price is driven by scientific breakthroughs, not market cycles. Its performance is completely disconnected from overall economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Abeona Therapeutics
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its stock has experienced a typical biotech rollercoaster this week, driven by news of FDA decisions, clinical trial data, and the need for additional funding to continue research.
Weekly dynamics of market capitalization of the market segment - Specialized pharma
Biotech companies working on rare diseases, like Abeona, are driven by news of clinical trials. The success or failure of one player often impacts the entire niche. The graph below shows this overall pulse. It allows one to assess how promising the market perceives Abeona's technology compared to competitors' developments.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Abeona Therapeutics specializes in gene and cell therapy for rare diseases. Its stock is a classic biotech, whose performance is 100% dependent on news about trials and FDA decisions. The chart clearly demonstrates this disconnect from the broader market.
Market capitalization of the company, segment and market as a whole
ABEO - Market capitalization of the company Abeona Therapeutics
Abeona Therapeutics' market capitalization chart reflects investors' assessment of its focus on cell and gene therapy for rare skin diseases. Its dynamics reflect the market's confidence in its drugs, which may offer hope to patients with epidermolysis bullosa. The company's value is a bet on regulatory approval and a successful commercial launch.
ABEO - Share of the company's market capitalization Abeona Therapeutics within the market segment - Specialized pharma
Abeona Therapeutics is a biopharmaceutical company specializing in gene and cell therapies for rare diseases. In its niche segment, its market capitalization is entirely dependent on progress in clinical trials. This metric's dynamics reflect investors' confidence in the company's ability to commercialize its breakthrough, yet risky, developments.
Market capitalization of the market segment - Specialized pharma
This chart shows the overall market capitalization of the entire biotech sector. For Abeona Therapeutics, which works on gene and cell therapies for rare diseases, this line represents an ocean of risk and hope. Its dynamics reflect the willingness of investors to invest in breakthrough but highly risky technologies, the success of which is crucial to the company's survival.
Market capitalization of all companies included in a broad market index - GURU.Markets
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its market cap, like that of many biotech companies, reflects its scientific potential and investors' faith in the success of its developments, which could change the lives of patients.
Book value capitalization of the company, segment and market as a whole
ABEO - Book value capitalization of the company Abeona Therapeutics
Abeona Therapeutics is a company specializing in gene and cell therapy for rare diseases. Its book value is derived from its manufacturing and research base: its own GMP facilities and cash for clinical trials. How has this foundation grown? The chart below shows this trend.
ABEO - Share of the company's book capitalization Abeona Therapeutics within the market segment - Specialized pharma
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its technologies require sophisticated infrastructure, including its own GMP-compliant manufacturing facility to create its personalized medications. The chart shows the company's share of the physical infrastructure required for this cutting-edge field of medicine.
Market segment balance sheet capitalization - Specialized pharma
Abeona Therapeutics, a gene and cell therapy company, is a capital-intensive business. It requires in-house manufacturing capabilities to create its complex drugs. The BCap_Seg chart for the biotech sector shows that commercializing such technologies requires a substantial financial base.
Book value of all companies included in the broad market index - GURU.Markets
Abeona Therapeutics's capital comes from its manufacturing capabilities for cell and gene therapies, as well as its portfolio of patents for drugs treating rare diseases. Its book value reflects its unique scientific and manufacturing capabilities. The chart below shows the net worth of this biotech innovator.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Abeona Therapeutics
Abeona's balance sheet represents its R&D and manufacturing assets. Its market value, which is lower than its book value, reflects past clinical trial failures and investor doubts about its ability to bring its developments to market. The chart represents a discount for its history of disappointments.
Market to book capitalization ratio in a market segment - Specialized pharma
Abeona Therapeutics is a cell and gene therapy company. Its valuation on this chart reflects both the potential of its technologies and the high risks associated with clinical development and manufacturing of such complex drugs, which require significant investment.
Market to book capitalization ratio for the market as a whole
Abeona Therapeutics is a company developing gene and cell therapies for rare diseases. Its market value depends almost entirely on the success of clinical trials. This chart clearly demonstrates the vast gap between its book value and the market valuation based on investor hopes.
Debts of the company, segment and market as a whole
ABEO - Company debts Abeona Therapeutics
Abeona Therapeutics, a company developing gene and cell therapies for rare diseases, uses capital to fund its crucial clinical trials and prepare for commercialization. This chart shows how the company manages its limited resources during the final and most expensive stage of drug development.
Market segment debts - Specialized pharma
Abeona Therapeutics is a company developing gene and cell therapies for rare diseases. The recent FDA approval of its first product is changing the financial landscape, but commercialization is expensive. This chart shows how the company is funding this transition from R&D to sales, balancing new revenue with existing expenses.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Abeona Therapeutics
Abeona Therapeutics develops gene and cell therapies for rare diseases. The financial model of such companies is built on expectations. This chart shows the company's reliance on debt and investor capital. It reflects the financial risk, which will only be mitigated by the successful approval and commercialization of its drugs.
Market segment debt to market segment book capitalization - Specialized pharma
Abeona Therapeutics develops gene and cell therapies to treat rare genetic diseases. The path from lab to patient in this field is particularly long and complex. This chart shows how the biotech sector uses debt to finance such breakthrough but risky technologies, and how Abeona compares.
Debt to book value of all companies in the market
Abeona Therapeutics, which specializes in gene and cell therapies for rare diseases, is pursuing extremely expensive developments. This chart, which reflects the overall market leverage, allows one to assess the company's financial risks. It demonstrates how its capital raising strategy aligns with the high standards and risks of the advanced biotech sector.
P/E of the company, segment and market as a whole
P/E - Abeona Therapeutics
Abeona Therapeutics develops gene and cell therapies for the treatment of rare genetic diseases. This chart shows how the market values its development pipeline. The company's valuation depends entirely on clinical trial results, regulatory approval, and the commercial potential of its innovative treatments.
P/E of the market segment - Specialized pharma
Abeona Therapeutics develops gene and cell therapies. This chart shows the average valuation for the biotech sector. It serves as a backdrop for Abeona's valuation: investors focus not on its profits but on the potential of its developments, making its valuation dependent on clinical trial news.
P/E of the market as a whole
Abeona Therapeutics is a biopharmaceutical company focused on developing gene and cell therapies for the treatment of rare and life-threatening diseases. This chart reflects the overall risk appetite of investors in biotech. It helps understand whether ABEO's valuation is based on the potential of its lead candidates or whether it moves in line with overall industry sentiment.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Abeona Therapeutics
Abeona Therapeutics develops gene and cell therapies for the treatment of rare genetic diseases. The company's future profitability is entirely dependent on the approval and commercial success of its drugs. This chart represents speculative market expectations regarding the potential of its cutting-edge scientific developments.
%20P%2FE%20Abeona%20Therapeutics&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Abeona-Therapeutics&v=1772513865994 "Chart of the company's future (projected) P/E Abeona Therapeutics")
Future (projected) P/E of the market segment - Specialized pharma
Abeona Therapeutics develops gene and cell therapies for rare and life-threatening diseases. The data here reflects the analysts' collective bets on the success of its clinical programs. It is a barometer of expectations for its innovative approaches to achieve regulatory approval and commercial success.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Specialized-pharma&v=1772513866049 "Future (projected) P/E graph of the market segment - Specialized pharma")
Future (projected) P/E of the market as a whole
Abeona Therapeutics is a biotech company focused on gene and cell therapies for rare diseases. This market outlook chart is critically important, as it determines the availability of funding for companies whose products require lengthy and expensive clinical trials before reaching the market.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513866120 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Abeona Therapeutics
Abeona Therapeutics is a biotechnology company developing gene and cell therapies for rare diseases. This chart shows the financial costs of bringing complex treatments to patients. It reflects investments in manufacturing processes and clinical trials, the success of which is critical to the company's survival.
Profit of companies in the market segment - Specialized pharma
Abeona Therapeutics is a biopharmaceutical company focused on cell and gene therapy for rare diseases. Currently in the clinical stage, it invests in the development of breakthrough treatments. Its financial history is a classic example of biotech, where long-term investments in science can lead to the creation of valuable assets.
Overall market profit
Abeona Therapeutics is a biotech company developing gene and cell therapies for rare diseases. Its success depends entirely on scientific and clinical results. This market performance chart is critical for Abeona, as it determines its ability to attract funding to bring its complex and expensive treatments to market.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Abeona Therapeutics
Abeona Therapeutics is a biopharmaceutical company developing gene and cell therapies for rare diseases. This chart reflects analysts' speculative expectations. Future profits are entirely dependent on regulatory approval and the successful commercial launch of their drugs, which is a critical factor for the company.
%20profit%20of%20the%20company%20Abeona%20Therapeutics&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Abeona-Therapeutics&v=1772513866354 "Graph of future (projected) profit of the company Abeona Therapeutics")
Future (predicted) profit of companies in the market segment - Specialized pharma
Abeona Therapeutics develops gene and cell therapies for rare and life-threatening diseases. The profitability projections for this sector, shown in the chart, show high potential but also significant risks associated with clinical trials. This chart provides context for assessing how close Abeona's drugs are to regulatory approval.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Specialized-pharma&v=1772513866416 "Graph of future (predicted) profits of companies in a market segment - Specialized pharma")
Future (predicted) profit of the market as a whole
Abeona Therapeutics is a company developing gene and cell therapies for rare diseases. Its value is based on the potential of its scientific developments. Financing such long-term, capital-intensive projects becomes easier in a strong and optimistic stock market, which often accompanies a positive outlook, as seen in this chart.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513866481 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Abeona Therapeutics
Abeona Therapeutics is a biopharmaceutical company specializing in gene and cell therapies for rare diseases. Its revenue may be limited. This chart shows how investors view its scientific pipeline and the commercial potential of its late-stage drugs.
P/S market segment - Specialized pharma
Abeona Therapeutics is a biotechnology company focused on developing gene and cell therapies for the treatment of rare and life-threatening diseases. This metric reflects the average revenue estimate for the sector and helps assess the level of investor confidence in the success of Abeona's clinical programs and its ability to bring its drugs to market.
P/S of the market as a whole
Abeona Therapeutics is a biopharmaceutical company developing gene and cell therapies for the treatment of rare genetic diseases, particularly epidermolysis bullosa. This chart provides an opportunity to assess how the market perceives companies with established revenues, which serves as a backdrop for analyzing biotech companies close to commercialization.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Abeona Therapeutics
Abeona Therapeutics develops gene and cell therapies for the treatment of rare genetic diseases. This chart reflects investors' high valuation of its potential future revenue. This valuation is based on the belief that its drug candidates will successfully complete clinical trials and reach the market.
%20P%2FS%20Abeona%20Therapeutics&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Abeona-Therapeutics&v=1772513866648 "The graph of the company's future (projected) P/S Abeona Therapeutics")
Future (projected) P/S of the market segment - Specialized pharma
Abeona Therapeutics develops gene and cell therapies for the treatment of rare genetic diseases. This chart compares market expectations for its future revenue with those of other specialty pharmaceutical companies. This valuation reflects investor expectations for regulatory approval and subsequent commercial success of its drugs.
%20P%2FS%20market%20segment%20graph%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Specialized-pharma&v=1772513866678 "Future (projected) P/S market segment graph - Specialized pharma")
Future (projected) P/S of the market as a whole
Abeona Therapeutics is a biotech company developing gene and cell therapies for rare diseases. Its success depends entirely on clinical trial results and regulatory approval. This overall revenue expectation schedule is irrelevant for Abeona, whose value is created in laboratories and clinics, not in the general market.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513866742 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Abeona Therapeutics
This chart visualizes the revenue of Abeona Therapeutics, a biotech company developing gene and cell therapies for rare genetic diseases. Having recently received approval for its first product, the company is beginning to generate its first commercial revenue. The chart's dynamics will reflect the success of this drug's market launch.
Sales of companies in the market segment - Specialized pharma
Abeona Therapeutics is a biopharmaceutical company focused entirely on developing gene and cell therapies for the treatment of rare and life-threatening diseases. This chart shows revenue in the specialty pharmaceuticals sector. It reflects the significant potential and high risks associated with developing cutting-edge therapies for orphan diseases, where Abeona strives to achieve breakthroughs.
Overall market sales
Abeona Therapeutics is a biotechnology company focused on gene and cell therapies for rare diseases. The company's success depends solely on clinical trial results and regulatory approval. This overall economic activity schedule doesn't directly impact its operations, but the overall wealth growth provides long-term funding for healthcare innovation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Abeona Therapeutics
Abeona Therapeutics is a commercial-scale company specializing in cell and gene therapy for rare skin diseases. This projected revenue chart reflects expectations for the launch of its first products. This increase is driven by expectations for successful market launches and physician adoption of its innovative treatments, which should begin generating stable revenue.
%20sales%20of%20the%20company%20Abeona%20Therapeutics&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Abeona-Therapeutics&v=1772513866955 "Schedule of future (projected) sales of the company Abeona Therapeutics")
Future (projected) sales of companies in the market segment - Specialized pharma
Abeona Therapeutics is a biopharmaceutical company specializing in the development of gene and cell therapies for the treatment of rare and life-threatening genetic diseases. This chart shows projected revenues for the entire specialty pharmaceutical sector, reflecting the high risks and potentially enormous rewards of treating orphan diseases.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Specialized-pharma&v=1772513866998 "Schedule of future (projected) sales of companies in the market segment - Specialized pharma")
Future (projected) sales of the market as a whole
Abeona Therapeutics develops gene and cell therapies for rare diseases. The company's success depends on scientific breakthroughs and regulatory approvals. The overall economic climate impacts the ability of healthcare systems and insurance companies to cover such expensive and innovative treatments.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513867046 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Abeona Therapeutics
Abeona Therapeutics develops gene and cell therapies for rare diseases. Like many biotech companies, it does not yet have stable revenue. This chart shows the intensity of its R&D activities, expressed as operating losses, which are investments in future breakthrough treatments.
Market segment marginality - Specialized pharma
Abeona Therapeutics is a biotech company specializing in gene and cell therapies for rare diseases. This chart shows its financial performance. For a company in the commercialization stage of its first drug, profitability can fluctuate dramatically, and a comparison with the industry benchmark will reveal how successful the product's launch was.
Market marginality as a whole
Abeona Therapeutics is a biotechnology company developing gene and cell therapies for the treatment of rare genetic diseases. Its value is not tied to the overall economic indicators reflected in this chart. The key indicators are progress in clinical trials and regulatory approvals of its drugs.
Employees in the company, segment and market as a whole
Number of employees in the company Abeona Therapeutics
Abeona Therapeutics is a biotechnology company focused on gene and cell therapies for rare diseases. This graph shows the team's scientific staff. The staffing dynamics reflect progress in clinical trials and investments in building in-house manufacturing capabilities for these complex drugs.
Share of the company's employees Abeona Therapeutics within the market segment - Specialized pharma
Abeona Therapeutics is a company focused on cell and gene therapy for rare diseases. The development and production of such complex treatments requires a small but highly specialized team. This underscores the company's research-intensive nature, reflecting its presence in the pool of talent working at the forefront of genetic medicine.
Number of employees in the market segment - Specialized pharma
Abeona Therapeutics is a biotech company specializing in cell and gene therapies for rare skin diseases. This chart illustrates the long road to approval of breakthrough treatments. The personnel dynamics reflect progress in clinical trials and preparation for commercial launch, which requires building manufacturing capacity and a sales team.
Number of employees in the market as a whole
Abeona Therapeutics is a company working in gene and cell therapy for rare diseases. The growth of its scientific and clinical staff is directly linked to research progress and regulatory approvals. This overall employment chart illustrates that creating jobs in advanced medicine is a long and risky process.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Abeona Therapeutics (ABEO)
Abeona Therapeutics is a biopharmaceutical company specializing in gene and cell therapies for rare genetic diseases, such as epidermolysis bullosa. This chart demonstrates the enormous cost per employee. This is typical for biotech, where market valuations are based on the potential of one or two drugs for treating orphan diseases.
%20of%20the%20company%20Abeona%20Therapeutics%20(ABEO)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Abeona-Therapeutics-ABEO&v=1772513867372 "Chart of market capitalization per employee (in thousands of dollars) of the company Abeona Therapeutics (ABEO)")
Market capitalization per employee (in thousands of dollars) in the market segment - Specialized pharma
Abeona Therapeutics is a biopharmaceutical company developing gene and cell therapies for rare diseases. In this complex and capital-intensive field, this chart reflects investor expectations. A high value indicates that the market sees significant potential in their research and developments and is willing to finance the long road to commercialization.
%20by%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Specialized-pharma&v=1772513867409 "Market capitalization per employee (in thousands of dollars) by market segment - Specialized pharma")
Market capitalization per employee (in thousands of dollars) for the overall market
Abeona Therapeutics is a biotech company focused on gene and cell therapies for rare diseases. This metric reflects a business at the forefront of medicine. Its market capitalization is based on the potential of its scientific developments. A small team of scientists is working to develop treatments that can change the lives of patients.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513867452 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Abeona Therapeutics (ABEO)
Abeona Therapeutics is a biotech company working on gene and cell therapy for rare diseases (e.g., epidermolysis bullosa). They are in the late clinical stage. This graph shows the loss per employee (R&D costs), but this could change dramatically if their drugs are approved.
%20Chart%20Abeona%20Therapeutics%20(ABEO)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Abeona-Therapeutics-ABEO&v=1772513867457 "Company Profit Per Employee (in thousands of dollars) Chart Abeona Therapeutics (ABEO)")
Profit per employee (in thousands of dollars) in the market segment - Specialized pharma
Abeona Therapeutics is a biotech company developing cell and gene therapies for rare diseases. The company is profitless. This metric reflects R&D capital burn per employee, which compares favorably with benchmarks in the extremely expensive orphan drug development sector.
%20in%20the%20market%20segment%20-%20Specialized%20pharma&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Specialized-pharma&v=1772513867530 "Chart of profit per employee (in thousands of dollars) in the market segment - Specialized pharma")
Profit per employee (in thousands of dollars) for the market as a whole
Abeona Therapeutics is another company working in gene and cell therapy for rare diseases. They are in late-stage R&D. This graph shows huge negative values—the colossal costs per scientist and doctor required to develop, manufacture, and clinically test these complex "living" drugs.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513867574 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Abeona Therapeutics (ABEO)
Abeona Therapeutics is a biopharmaceutical company developing gene and cell therapies for rare diseases. This chart shows the company's business at the clinical development stage. Zero revenue per employee is normal for a company whose value is determined by the potential of its breakthrough treatments.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Abeona-Therapeutics-ABEO&v=1772513867663 "Sales chart per company employee Abeona Therapeutics (ABEO)")
Sales per employee in the market segment - Specialized pharma
Abeona Therapeutics (ABEO) is a biotech company specializing in cell and gene therapies for rare (orphan) diseases, specifically epidermolysis bullosa. This chart shows the revenue (from partnerships) generated by each employee (scientist). This is an indicator of the productivity of their R&D platform in the orphan disease niche.
Sales per employee for the market as a whole
Abeona Therapeutics (ABEO) is a biopharmaceutical company specializing in gene and cell therapies for rare diseases (such as epidermolysis bullosa). This is an R&D business. The company has no commercial revenue from drug sales. This figure is currently close to zero.
Short shares by company, segment and market as a whole
Shares shorted by company Abeona Therapeutics (ABEO)
Abeona Therapeutics is a biotech company developing gene and cell therapies for rare diseases. This chart measures bearish bets. Bearish bets are placed on a high risk of trial failure or on the company burning through all its capital before bringing its complex product to market.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Abeona-Therapeutics-ABEO&v=1772513867798 "Short Shares Chart for the Company Abeona Therapeutics (ABEO)")
Shares shorted by market segment - Specialized pharma
Abeona Therapeutics is a biotech company developing cell and gene therapies for the treatment of rare skin diseases (epidermolysis bullosa). This metric measures pessimism. "Shorts" here are bets that their therapy will not receive FDA approval or will fail to reach the market.
Shares shorted by the overall market
Abeona Therapeutics is another company working in gene and cell therapy for rare diseases. This chart shows the overall level of pessimism in the market. When investors are fearful, biotech stocks, which require huge amounts of capital for research, become extremely vulnerable. The risk that the company will be unable to raise capital increases.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Abeona Therapeutics (ABEO)
Abeona Therapeutics (ABEO) is a biotech company specializing in gene and cell therapies for a rare skin disease (epidermolysis bullosa). This chart measures hype. It shows "overheated" (above 70) on news of their drug's FDA approval or "oversold" (below 30) amid delays or the need for funding.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Abeona-Therapeutics-ABEO&v=1772513867946 "RSI 14 indicator chart for the company's stock Abeona Therapeutics (ABEO)")
RSI 14 Market Segment - Specialized pharma
Abeona (ABEO) is a biotech company focused on gene therapy (AAV) for the treatment of severe skin diseases (epidermolysis bullosa). The RSI_14_Seg for "Specialized Pharma" (biotech) shows the overall sentiment. The chart helps us understand: is ABEO's volatility due to its R&D or is the entire sector overheated?
RSI 14 for the overall market
Abeona Therapeutics (ABEO) is a biotech company. Like everything in its sector, it's critically dependent on this schedule. Market euphoria offers the potential to easily raise hundreds of millions of dollars for research. Market panic risks running out of money before its breakthrough technologies reach patients.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast ABEO (Abeona Therapeutics)
Abeona Therapeutics is a biotech company focused on gene therapy for rare skin diseases, particularly epidermolysis bullosa. This chart shows the analysts' average 12-month forecast. Their target price is entirely dependent on FDA decisions and the potential commercial launch of their drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-ABEO-Abeona-Therapeutics&v=1772513868038 "A chart showing analyst consensus forecasts for the expected stock price. ABEO (Abeona Therapeutics)")
The difference between the consensus estimate and the actual stock price ABEO (Abeona Therapeutics)
Abeona Therapeutics is a company specializing in gene and cell therapies for severe, rare diseases, primarily epidermolysis bullosa (a butterfly disease). This chart shows the difference between the market valuation and the analyst consensus forecast. It indicates whether experts believe their drugs will be approved and launched.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-ABEO-Abeona-Therapeutics&v=1772513868089 "A chart showing the difference between the consensus forecast and the actual stock price. ABEO (Abeona Therapeutics)")
Analyst consensus forecast for stock prices by market segment - Specialized pharma
Abeona Therapeutics is a biotech company focused on gene and cell therapies for the treatment of rare bullous skin diseases (where the skin peels). This chart shows general expectations for the specialty pharmaceutical sector. It reflects whether experts believe breakthroughs in the treatment of ultra-rare genetic diseases are possible.
Analysts' consensus forecast for the overall market share price
Abeona Therapeutics is a biotech company specializing in gene and cell therapies for rare diseases, particularly "butterfly babies" (epidermolysis bullosa). This chart shows the overall risk appetite. For Abeona, whose valuation depends on regulatory approval, overall market optimism is important for funding, but news from the FDA carries far more weight.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Abeona Therapeutics
Abeona Therapeutics is a biotech company focused on gene and cell therapies for rare, life-threatening diseases (such as butterfly babies). This chart is an assessment of their R&D pipeline. It reflects their progress in clinical trials and their ability to overcome the complex manufacturing and regulatory hurdles in this cutting-edge field.
AKIMA Market Segment Index - Specialized pharma
Abeona (ABEO) is a clinical-stage biotech and a leader in gene therapy, developing breakthrough treatments for rare bullous skin diseases (EB). This summary metric evaluates R&D. The graph shows the segment average. This benchmark: how does this ultra-niche (R&D) focus (ABEO) differentiate it from the average pharma company?
The AKIM Index for the overall market
Abeona Therapeutics is a gene and cell therapy company developing a treatment for a rare skin disease (epidermolysis bullosa). This chart, which reflects the market average, provides a macro backdrop. It helps assess how this company, which is approaching potential approval, compares to overall economic trends in the sector.
